SCHEMBL1240249

SCHEMBL1240249

C[Si](C)(CCCN)O[Si](O[Si](C)(C)CCCN)(O[Si](C)(C)CCCN)c1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.34
HTR2A P28223 1/20 0.33
HRH1 P35367 1/20 0.33
KIF11 P52732 3/20 0.32
KCNH2 Q12809 1/20 0.32
MGAM O43451 1/20 0.31
TAAR1 Q96RJ0 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15489983 0.94 TLR8 (0.34) MAOAHTR2AHRH1
SCHEMBL20565391 0.87 MAOA (0.35) MAOAHTR2AHRH1KIF11KCNH2
SCHEMBL20000036 0.86 MAOA (0.34) MAOAHTR2AHRH1KIF11KCNH2
SCHEMBL12546076 0.84 MAOA (0.33) MAOAHTR2AHRH1KIF11KCNH2
SCHEMBL13878405 0.84 MAOA (0.33) MAOAHTR2AHRH1KIF11KCNH2
SCHEMBL3418590 0.84 HRH1 (0.36) MAOAHTR2AHRH1KIF11KCNH2
SCHEMBL13878406 0.83 MAOA (0.32) MAOAHTR2AHRH1KIF11KCNH2
SCHEMBL12695267 0.83 MAOA (0.32) MAOAHTR2AHRH1KIF11KCNH2
SCHEMBL676715 0.80 MAOA (0.31) MAOAHTR2AHRH1
SCHEMBL12634222 0.80 HTR2A (0.33) MAOAHTR2AHRH1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024039914-A1 SORBENTS FUNCTIONALIZED WITH LIGANDS HAVING AN AMINOSILICONE FUNCTIONAL GROUP GENERAL ELECTRIC TECHNOLOGY GMBH (CH) 2024-02-22 WO disclosed
US-9914098-B2 Flux enhancing agent for improving composite polyamide reverse osmosis membrane performance BL TECHNOLOGIES, INC. 2018-03-13 US disclosed
US-9914098-B2 Flux enhancing agent for improving composite polyamide reverse osmosis membrane performance BL TECHNOLOGIES, INC. 2018-03-13 US disclosed
US-20160193572-A1 Novel Flux Enhancing Agent for Improving Composite Polyamide Reverse Osmosis Membrane Performance BL TECHNOLOGIES, INC. 2016-07-07 US disclosed
US-20160193572-A1 Novel Flux Enhancing Agent for Improving Composite Polyamide Reverse Osmosis Membrane Performance BL TECHNOLOGIES, INC. 2016-07-07 US disclosed
US-9346023-B2 Flux enhancing agent for improving composite polyamide reverse osmosis membrane performance GENERAL ELECTRIC COMPANY (US) 2016-05-24 US disclosed
US-20140054228-A1 Novel Flux Enhancing Agent for Improving Composite Polyamide Reverse Osmosis Membrane Performance GENERAL ELECTRIC COMPANY (US) 2014-02-27 US disclosed
US-8030509-B2 Carbon dioxide absorbent and method of using the same GENERAL ELECTRIC COMPANY (US) 2011-10-04 US disclosed
US-8030509-B2 Carbon dioxide absorbent and method of using the same GENERAL ELECTRIC COMPANY (US) 2011-10-04 US disclosed
WO-2011014273-A1 CARBON DIOXIDE ABSORBENT AND METHOD OF USING THE SAME GENERAL ELECTRIC COMPANY (US) 2011-02-03 WO disclosed
US-20100158777-A1 CARBON DIOXIDE ABSORBENT AND METHOD OF USING THE SAME GENERAL ELECTRIC COMPANY (US) 2010-06-24 US disclosed
US-20100158777-A1 CARBON DIOXIDE ABSORBENT AND METHOD OF USING THE SAME GENERAL ELECTRIC COMPANY (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100158777-A1 CARBON DIOXIDE ABSORBENT AND METHOD OF USING THE SAME MCM4, MCM5, IPO4 MAOA 2506/4885HTR2A 3015/4885HRH1 2736/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.